SCNX Overview

Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Wall Street analysts forecast SCNX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCNX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Scienture Holdings Inc revenue for the last quarter amounts to 590.05K USD, increased 809.71

Scienture Holdings Inc. EPS for the last quarter amounts to -0.19 USD, decreased -85.82

Scienture Holdings Inc (SCNX) has 14 emplpoyees as of March 20 2026.

Today SCNX has the market capitalization of 18.58M USD.